FDA Approval and Mechanism of Action

Krystexxa (pegloticase) is a biologic agent that utilizes pegylated recombinant uricase, which converts uric acid into allantoin. The FDA approved BLA 125293 on September 14, 2010, for the treatment of adult chronic refractory gout that has failed to respond to or is intolerant of maximum doses of xanthine oxidase inhibitors. On June 16, 2009, the FDA Arthritis Advisory Committee recommended approval by a vote of 14 to 1, based on efficacy and safety data. It is currently approved and marketed in the United States and is not recommended for asymptomatic hyperuricemia.

Clinical Evidence and Safety

The initial approval was based on results from two randomized, placebo-controlled Phase 3 trials evaluating 8 mg intravenous infusions every two weeks. A subsequent 52-week, randomized, double-blind MIRROR trial, which enrolled 152 patients, provided evidence that weekly administration of 15 mg methotrexate in combination with Krystexxa resulted in a higher sustained uric acid response compared to Krystexxa alone. The FDA incorporated this combination therapy information into the label on July 7, 2022. The 6-month response rate in the methotrexate combination group was 71%, compared to 39% in the monotherapy group, demonstrating clinical significance in mitigating anti-drug antibody and treatment failure issues. However, the boxed warning for anaphylaxis and infusion reactions, the contraindication for G6PD deficiency, and the requirement for serum uric acid monitoring prior to administration are important safety management conditions for commercial expansion.

Market and Competitive Landscape

The standard first-line treatment is xanthine oxidase inhibitors such as allopurinol and febuxostat, and colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs) are used for the prevention of acute attacks. Krystexxa is a rare disease asset with no direct competitors in the U.S. market for refractory gout, and the company previously estimated that approximately 120,000 patients in the U.S. could benefit from treatment. Amgen's 2025 Krystexxa sales are projected to be USD 1.34 billion, a 13% increase year-over-year, which is the most direct indicator of the realized U.S. market size. A competing pipeline product, NASP from Swedish Orphan Biovitrum AB (SOBI), is a combination of nanocapsulated sirolimus and pegadricase and is currently under BLA review, with an FDA target action date of June 27, 2026.

Regulatory Scope and Investment Implications

In Europe, it was approved on January 8, 2013, but the approval was withdrawn on June 30, 2016, due to the company's commercial decision. In Japan, it is not listed as an approved product by the PMDA, so sales are concentrated in the United States. This structure provides strong pricing power through high treatment costs and limited direct competition, while also increasing dependence on insurance coverage and access to infusion centers in a single region. The 2025 sales growth and the effectiveness of methotrexate combination therapy support Amgen's expansion of patient penetration, but the 2026 regulatory decision for NASP, which is under BLA review, will be a key catalyst for changing the monopoly structure. Therefore, this FDA record is not just an administrative announcement but a benchmark for evaluating the long-term clinical differentiation and competitive entry point of the approved asset.